IP Library Granted Patent US 8,684,998
Granted Patent B2
US 8,684,998 · App. 13/417,044 · Granted Apr 1, 2014

Methods for inhibiting renal nerve activity

Inventors: Denise Demarais (Saratoga, CA); Nicolas Zadno (Fremont, CA); Benjamin J. Clark (Redwood City, CA); Erik Thai (San Jose, CA); Howard R. Levin (Teaneck, NJ); Mark Gelfand (New York, NY)
Assignee: Medtronic Ardian Luxembourg S.a.r.l.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,684,998
App. No.
13/417,044
Granted
Apr 1, 2014
Kind
B2
Abstract

Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.

Claims (20)

1. A method for performing a renal denervation procedure, the method comprising:

percutaneously delivering an intravascular catheter through an abdominal aorta of a human patient to a renal blood vessel of the patient and proximate to renal nerves;

delivering a neuromodulatory agent via the catheter to at least partially inhibit neural signaling along the renal nerves; and

removing the catheter from the patient after delivering the neuromodulatory agent to conclude the procedure.

2. The method of claim 1 wherein delivering a neuromodulatory agent to the renal nerves comprises delivering phenol.

3. The method of claim 1 wherein delivering a neuromodulatory agent to the renal nerves comprises delivering a neurotoxin.

4. The method of claim 1 wherein delivering a neuromodulatory agent to the renal nerves comprises delivering botulinum toxin.

5. The method of claim 1 wherein delivering a neuromodulatory agent via the catheter comprises delivering fluid to block neural signaling along the renal nerves.

6. The method of claim 1 wherein delivering a neuromodulatory agent via the catheter comprises delivering an agent to necrose the renal nerves.

7. The method of claim 1 wherein percutaneously delivering an intravascular catheter through an abdominal aorta of a human patient to a renal blood vessel comprises delivering the catheter to the renal blood vessel via a guidewire.

8. The method of claim 1 wherein delivering a neuromodulatory agent via the catheter comprises delivering fluid to only partially block neural signaling along the renal nerves.

9. The method of claim 1 wherein delivering the neuromodulatory agent to at least partially inhibit neural signaling along the renal nerves alters at least one of urine production, fluid retention, renin secretion, waste excretion, sodium retention, systemic vasoconstriction, renal function, heart function and blood pressure in the patient.

10. The method of claim 9 wherein altering urine production comprises increasing urine output.

11. The method of claim 9 wherein altering renin secretion comprises decreasing renin secretion.

12. The method of claim 9 wherein altering sodium retention comprises increasing sodium excretion.

13. The method of claim 1 wherein delivering the neuromodulatory agent to at least partially inhibit neural signaling along the renal nerves comprises systemically reducing sympathetic tone in the patient.

14. The method of claim 1 wherein delivering the neuromodulatory agent to at least partially inhibit neural signaling along the renal nerves results in a therapeutically beneficial reduction in blood pressure in the patient.

15. The method of claim 1 wherein percutaneously delivering an intravascular catheter through an abdominal aorta of a human patient to a renal blood vessel comprises positioning the catheter within a renal artery of the patient.

16. The method of claim 1 wherein percutaneously delivering an intravascular catheter through an abdominal aorta of a human patient to a renal blood vessel comprises positioning the catheter within a renal vein of the patient.

17. The method of claim 1 wherein delivering the neuromodulatory agent to at least partially inhibit neural signaling comprises reducing afferent and/or efferent renal neural activity.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2013
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 030531/0717 →
CHANGE OF NAME Recorded Jun 3, 2013
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 030531/0816 →
Continuity (13)
Continuation 12700524 · Feb 4, 2010
Continuation 11840142 · Aug 16, 2007
Continuation 11504117 · Aug 14, 2006
Continuation In Part 10408665 · Apr 8, 2003
Continuation In Part 11189563 · Jul 25, 2005
Continuation In Part 11129765 · May 13, 2005
Provisional Application 60816999 · Jun 28, 2006
Provisional Application 60370190 · Apr 8, 2002
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60442970 · Jan 29, 2003
Provisional Application 60616254 · Oct 5, 2004
Provisional Application 60624793 · Nov 2, 2004
Related Publication 20120172837A1 · Jul 5, 2012